Advertisements

Muclear (Acetylcysteine)

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Muclear (Acetylcysteine)

What is Muclear (Acetylcysteine)?

Muclear is a medicinal product containing the active substance acetylcysteine. It belongs to a group of medicines known as mucolytics, which are used to help manage conditions characterized by the presence of thick, viscous mucus in the respiratory tract.

Mechanism of Action

Acetylcysteine works by chemically altering the structure of mucus. It contains a free sulfhydryl group that interacts with the disulfide bonds found in the proteins (mucoproteins) that give mucus its thickness and elasticity. By breaking these bonds, the medication reduces the viscosity of the secretions, making them thinner and more fluid.

Primary Purpose

The primary function of Muclear is to facilitate the clearance of mucus from the airways. When secretions become less dense, they can be more easily moved by the natural filtration systems of the respiratory tract or expelled through coughing. This process helps to support airway patency and improve overall respiratory comfort in individuals experiencing congestion due to various underlying conditions.

Characteristics

  • Active Ingredient: Acetylcysteine.
  • Therapeutic Class: Mucolytic agent.
  • Functional Goal: Reduction of mucus viscosity to aid expectoration.

Regulatory References

  1. World Health Organization
Advertisements

What side effects are possible with Muclear (Acetylcysteine)?

Possible side effects and safety information

The safety profile for Muclear (Acetylcysteine) is documented based on frequency classifications and physiological systems affected, derived from official government regulatory sources, such as the FDA and EMA. The documented side effects typically involve the gastrointestinal and immune systems.


Adverse Reactions and System-Organ Classes

The most frequently classified adverse reactions are generally related to the Gastrointestinal Disorders (e.g., nausea and vomiting). Reactions involving the Skin and Subcutaneous Tissue Disorders (e.g., rash, urticaria, facial flushing, and pruritus) are also commonly cited in regulatory labeling.

Less frequently, Immune System Disorders may be affected, leading to documented hypersensitivity symptoms, including headache, tinnitus, and fever, categorized as uncommon in official documents.


Serious Adverse Reactions

The official safety profile includes explicit documentation of serious, though rare, adverse reactions. These include potentially life-threatening anaphylactic or anaphylactoid reactions and reports of serious cutaneous adverse reactions (SCARs), such as Stevens-Johnson syndrome and toxic epidermal necrolysis, reported in temporal association with use. The risk of upper gastrointestinal hemorrhage is also a specific safety consideration for vulnerable patients.


Population and Time-Related Safety Constraints

Specific safety considerations are noted for certain populations. For instance, the use of mucolytics, including Acetylcysteine, is generally not recommended in children under two years of age. Patients with asthma require close monitoring due to the documented potential for bronchospasm. Time-related patterns include the observation of anaphylactoid reactions soon after the initiation of an intravenous infusion, and the potential for bronchial secretions to increase in volume at the start of mucolytic treatment.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

Acetylcysteine, often used as an antidote, primarily addresses potential hepatic injury following an overdose of acetaminophen. Medical attention is considered urgent following the ingestion of a potentially hepatotoxic quantity of acetaminophen, which is generally defined as 150 mg/kg or more. The most effective window for administration is typically within the first eight hours of acute ingestion, as efficacy progressively diminishes with time.

Immediate medical help is required if a potentially hepatotoxic dose of acetaminophen has been ingested or if there is clinical evidence of acetaminophen toxicity. If the ingestion time is unknown or the acetaminophen level cannot be readily obtained or interpreted, Acetylcysteine administration should be initiated immediately if 24 hours or less have elapsed from the reported time of ingestion.

Overdose of Acetylcysteine itself, particularly massive intravenous overexposure, has been associated with serious central nervous system effects such as cerebrotoxicity, seizures, confusion, and in rare case reports, brain death. The infusion should be stopped immediately if an anaphylactoid reaction occurs, which requires prompt treatment with antihistamines and, in severe cases, epinephrine. The treatment protocol must be adjusted for populations with specific risks, such as pediatric patients under 40 kg or those with pre-existing conditions like malnutrition or chronic alcoholism.

Advertisements

Therapeutic Uses of Muclear (Acetylcysteine)

Muclear (Acetylcysteine) is commonly used to help with two principal applications, offering support in conditions where symptoms create noticeable physiological strain or require immediate systemic protection. The dual therapeutic role of Acetylcysteine is consistent with its established uses.


Easing Symptoms of Viscid Chest Congestion

This medication may be part of symptomatic management in conditions characterized by periods of heightened symptoms, such as Chronic Obstructive Pulmonary Disease (COPD), chronic bronchitis, and Cystic Fibrosis (CF). It is applied when patients experience difficulty due to abnormally thick and sticky mucus in the airways. The primary benefit is that it helps to ease the release of these viscid secretions, which may assist with making the phlegm easier to mobilize and cough up. This action contributes to improved comfort during periods of heightened respiratory symptoms.

“Applied in scenarios where additional management of discomfort is required, Muclear supports patients during difficult episodes by easing distress caused by thick, persistent secretions.”

Quick Fact: Relief for Respiratory Congestion This agent is relevant for easing symptoms related to the presence of inspissated (hardened) secretions, which are common in patients managing long-term bronchopulmonary conditions.


Supportive Management in Specific Toxicological Exposure

Muclear is considered relevant for acute scenarios that require supportive symptom management. It is commonly used to help with the acute management of exposure to potentially hepatotoxic doses of acetaminophen (paracetamol). Applied in clinical settings that involve acute or unstable symptom patterns, it plays a role in managing the body’s detoxification process, which is appropriate to provide supportive management against organ damage. This assists with maintaining functional stability and providing assistance during the patient's recovery process.

Regulatory References

  1. NIH MedlinePlus overview
Advertisements

Eligibility and Restrictions for Use

Acetylcysteine (Muclear) is primarily used as an antidote for acetaminophen (paracetamol) overdose and as a mucolytic agent to help thin thick mucus secretions in conditions like chronic bronchitis, cystic fibrosis, and pneumonia. Its use is generally considered safe, but certain precautions and contraindications exist.

Who Can Use Acetylcysteine Who Should Use Caution or Avoid
Patients with acetaminophen poisoning Individuals with a documented hypersensitivity or allergy to acetylcysteine.
Patients needing a mucolytic for various bronchopulmonary conditions Patients with severe asthma or a history of bronchospasm, as inhalation may worsen breathing difficulty.
Children and elderly patients, with appropriate dosage adjustments and close monitoring Patients with a history of esophageal varices or peptic ulcers, as oral administration may increase the risk of upper gastrointestinal hemorrhage.
Pregnant and breastfeeding women, particularly for acetaminophen overdose, after a careful risk-benefit assessment by a healthcare provider.

For mucolytic use, the drug may not be recommended for infants under two years old due to the difficulty this age group has with actively coughing up secretions, increasing the risk of airway obstruction.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation identifies specific medicinal products and substance categories that may interact with acetylcysteine (Muclear). These interactions are primarily defined by practical constraints on co-administration, requiring timing adjustments or close monitoring.


Documented Interacting Agents

Product Category Specific Agent (Example) Interaction Profile
Organic Nitrates Nitroglycerin Co-administration is not recommended due to potential for enhanced vasodilation, which may cause significant hypotension (low blood pressure) and headache.
Antibiotics Tetracycline (excluding Doxycycline and Minocycline) Requires a two-hour minimum separation between administration times to prevent possible reduction of the antibiotic effect in vitro.
Adsorbents Activated Charcoal Simultaneous oral administration should be avoided as activated charcoal may adsorb acetylcysteine, potentially reducing its overall availability.
Other Mucolytics Other Mucolytic Agents Clinical data regarding co-administration is limited, and specific interaction instructions are not defined in regulatory labeling.

Interaction-Related Constraints

The most clinically significant interaction requires caution when co-administered with organic nitrates, necessitating careful blood pressure monitoring if the combination is deemed necessary. The chemical incompatibility with certain tetracycline antibiotics requires a mandatory time separation to ensure the therapeutic effectiveness of the antibiotic is maintained. These specific regulatory requirements define the profile, focusing on avoiding simultaneous use of specific agents or managing enhanced effects.

Advertisements

Mechanism of Action

How Muclear (Acetylcysteine) Works

Acetylcysteine's action is defined by three primary mechanistic domains.

Augmenting the Cellular Antioxidant System

Acetylcysteine functions as a pro-drug, delivering the molecular precursor L-cysteine required for the synthesis of glutathione ( GSH), the cell's main intrinsic antioxidant molecule. This process restores the cellular capacity to neutralize harmful free radicals and stabilize the redox state, influencing the concentration of oxidized versus reduced molecules across various tissues.

Direct Modification of Secretion Viscosity

The molecule contains a free sulfhydryl ( -SH) group which acts as a reducing agent. This group directly breaks the disulfide bonds ( S-S) that link large mucin protein complexes. This chemical depolymerization decreases the viscosity and adhesiveness of secretions, thereby modifying their physical properties for subsequent physiological transport processes.

Modulation of Cellular Stress Signaling

By improving the cellular redox environment, the drug influences intracellular signaling pathways. This activity acts to inhibit the activation of pro-inflammatory transcription factors, such as Nuclear Factor kappa-B ( NF-kappa B), thereby contributing to the suppression of localized cellular inflammatory responses and diminishing the activity of subsequent biochemical cascades.

Advertisements

Dosage and Administration Information

How Muclear (Acetylcysteine) is Used

The administration of Acetylcysteine is governed by its two distinct clinical roles, which determine the route, dosage, and setting required for proper use. The medicine is approved for administration via oral, inhalation, or intravenous (IV) routes.


Dosing for Airway Secretion Management (Mucolytic Use)

For managing respiratory secretions, the medication is typically used in an outpatient setting. Standard adult oral dosing involves 600 mg once daily or 200 mg two to three times per day. This pattern allows for either divided daily dosing or a single daily dose. Mucolytic use may be continued for long-term maintenance in chronic conditions or used short-term for acute episodes. Oral dosage forms, such as effervescent tablets, must be fully dissolved in water before drinking, and the dose can generally be taken without regard to meals.


Dosing for Acute Toxicity Management (Antidote Use)

As an antidote, Acetylcysteine requires a highly specific, time-critical administration protocol performed in a hospital setting under supervision. Dosing for toxicity is weight-based (mg/kg) for both adults and children.

The Intravenous (IV) regimen involves a fixed course of approximately 21 hours in which a total dose of about 300 mg/kg is delivered sequentially over three bags, beginning with a loading dose of 150 mg/kg infused over 1 hour. The IV solution must be diluted in appropriate fluids before infusion. Alternatively, the oral antidote protocol consists of a total of 18 doses delivered over a 72-hour course, with maintenance doses administered every 4 hours. If an oral dose is vomited within 1 hour of administration, the full dose must be re-administered.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies


Research Focus: Knee Osteoarthritis

Studies evaluated whether the drug was associated with changes in joint function and pain in patients with knee osteoarthritis (OA). Research has explored properties of the drug.

  • Pain and Function: Studies examined whether the combination was associated with changes in overall quality of life in OA patients. The evaluation of results for the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) were a primary outcome measure in key trials.
  • Stiffness: A key study reported a reduction in joint stiffness observed at week 4 of treatment. Findings were mixed regarding the effect on morning stiffness compared to other measures of joint mobility.
  • Study Population: The majority of evidence is drawn from double-blind, randomized trials involving adult patients (aged 50–75) with moderate to severe symptomatic knee OA.

Comparative Research: Evaluation Against Other Treatments

Studies reported differences in outcomes when comparing the drug to placebo and other non-pharmacological methods.

  • Placebo Comparisons: Trial data reported a difference in the change from baseline in pain scores between the drug and placebo groups across four Phase 3 trials. However, researchers noted that the clinical relevance of this difference was a subject of further analysis.
  • Active Comparator Trials: Research has explored the drug's use in acute flare-ups. In a head-to-head trial against a common NSAID, no statistically significant difference in pain reduction was reported at the 12-week endpoint.
  • Adherence: Patient adherence rates were examined in studies. Overall, patient adherence was reported to be high, with discontinuations primarily related to non-serious adverse events.

Safety Profile

Side Effects: Findings from Research

The majority of reported side effects were classified as mild; however, studies have noted the importance of careful patient selection, particularly for those with pre-existing liver conditions.

  • Common Events: The most frequently reported adverse events across all studies included nausea, headache, and gastrointestinal discomfort.
  • Long-Term Data: Long-term studies have reported on the safety profile observed in adult populations. The data indicated that adverse events generally occurred within the first six months of treatment.
  • Serious Adverse Events (SAEs): Serious adverse events were reported at a low incidence, and these events were reported at a low incidence. No new, unexpected SAEs were identified in the 12-month extension studies.

Key Studies & References

  1. Study of the Effects of N-acetylcysteine on Inflammatory Biomarkers and Disease Activity Score in Patients with Rheumatoid Arthritis (RCT)
  2. N-Acetylcysteine (NAC) monograph - Texas Health and Human Services (Safety and Adverse Effects)
  3. Clinical trial on intra-articular N-acetyl cysteine versus hyaluronic acid in mild to moderate knee osteoarthritis (Pilot Study)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Muclear (Acetylcysteine) (FAQ)


Q: Besides its main use, are there other official uses for Muclear?

Official documents describe the primary uses of Muclear (Acetylcysteine) as both an antidote for specific toxicity and a mucolytic agent. Beyond these main roles, the medication is officially approved as an adjuvant therapy—meaning an additional treatment—for conditions involving abnormal, thick, or viscid mucous secretions, such as chronic bronchitis and cystic fibrosis.


Q: What happens if I miss a dose of Muclear?

Official patient information for the oral forms of Muclear generally advises taking a missed dose as soon as the patient remembers. However, if it is almost time for the next scheduled dose, the missed dose should be skipped entirely. To help maintain the treatment schedule, regulatory information states that the missed dose should not be doubled, and the patient should proceed with the next scheduled dose as planned.


Q: Is Muclear safe for use during pregnancy, according to official sources?

Official sources have assigned classifications for the use of Muclear during pregnancy. For instance, in the U.S., it is categorized as Pregnancy Category B, meaning animal reproduction studies have generally not shown a risk to the fetus, but controlled data from human pregnancy is unavailable. Official documentation indicates that the use of this medication during pregnancy is managed by a healthcare provider who assesses the potential benefit versus risk based on clinical need.


Q: Can Muclear be used while breastfeeding?

According to official product labeling, it is currently unknown whether Muclear's active ingredient, Acetylcysteine, is excreted into human milk. Official regulatory documents indicate that its use while breastfeeding requires a healthcare provider to assess the potential benefit against the unknown risk.


Q: How is Muclear described in official drug information sheets?

Official drug information sheets describe Muclear (Acetylcysteine) by its dual function as a mucolytic agent and an antidote for specific toxicity. These documents list key details such as known adverse reactions (e.g., nausea and rash), provide summaries of its mechanism of action, and outline important warnings and precautions for use in specific populations, such as patients with asthma.


Q: How quickly does Muclear leave the body?

Based on regulatory pharmacokinetics documents, the active ingredient, acetylcysteine, has a typical plasma half-life of approximately 5.6 hours in healthy adults following oral administration. The plasma half-life is a measure of the drug's elimination rate. This time may be longer in individuals who have impaired liver function.


Q: Does Muclear affect blood sugar levels?

Official regulatory documents, particularly those describing the antidote use of Muclear in a hospital setting, specify that a patient's blood glucose levels should be monitored during treatment. The necessity of monitoring suggests that blood sugar levels are a factor healthcare providers consider during the acute care setting.


Q: Can Muclear be taken with everyday vitamins or supplements?

Official regulatory documents do not provide specific instructions or defined interaction warnings for combining Muclear with most common vitamins or dietary supplements. It is important for patients to discuss all supplements being taken with a healthcare provider, as official documents do not list specific data for all potential supplement interactions.


Q: Are there any specific foods I should avoid while using Muclear?

Official labeling for the oral forms of Muclear states that the dose can generally be taken without regard to meals or food. Regulatory documents do not list any specific foods that must be strictly avoided during the course of treatment, unlike some other medications that have known food interactions.


Q: What should I do if I suspect an allergic reaction to Muclear?

Official warning sections emphasize that serious hypersensitivity reactions, including anaphylaxis, may occur, especially during intravenous administration. If symptoms of a severe allergic or hypersensitivity reaction are suspected, official warnings state that the medication should be discontinued and emergency medical attention should be sought.


Q: Is Muclear addictive or habit-forming?

Muclear (Acetylcysteine) is not classified as a controlled substance by regulatory bodies such as the U.S. Drug Enforcement Administration (DEA). Official product schedules do not list it as a substance with known abuse potential or that is habit-forming.


Q: Does Muclear affect the liver, and if so, how?

Muclear's active ingredient plays a direct role in liver function as an antidote. It works by acting as a precursor to glutathione, which is the cell’s primary antioxidant, helping the liver detoxify harmful substances and repair damage. Regulatory documents state that liver function is a factor that is monitored, particularly for patients with pre-existing liver conditions.


Q: Is there a link between Muclear and anxiety or mood changes?

Official adverse reaction lists for some drug formulations have reported headache as an uncommon side effect. However, regulatory labels do not specifically list anxiety or general mood changes as documented or common adverse reactions directly associated with the medication's use.


Q: Is Muclear available without a prescription?

Muclear (Acetylcysteine) is available in both prescription-only (Rx) forms and over-the-counter (OTC) forms in various regions and countries for specific indications. For instance, the intravenous injection used in hospitals and certain inhalation solutions typically require a prescription, while some oral forms may be available over the counter.


Q: Does Muclear have any known interactions with alcohol?

Official product documents do not list a direct chemical interaction between Muclear and alcohol consumption. However, regulatory labels state that chronic alcohol consumption may increase the risk of liver damage from certain toxic exposures, which is a condition Muclear is used to treat.


Q: Does Muclear have a strong or noticeable taste?

Official descriptions and patient instructions note that the active ingredient, Acetylcysteine, naturally possesses an unpleasant sour, sulfuric, or metallic taste and odor. Many oral formulations are manufactured with added flavors to modify these natural characteristics.


Q: Can Muclear be crushed or chewed?

Specific regulatory instructions for oral dosage forms, such as effervescent tablets or powder, require the medication to be fully dissolved in water before drinking. Official instructions for these forms specify that they must be dissolved in water and are not intended to be chewed or swallowed whole in their solid or powder state.


Q: What is the shelf life of Muclear after the package is opened?

The required shelf life after the packaging is opened varies significantly by the type of product. For example, diluted intravenous solutions must be used within a short, fixed period, such as 24 hours. Similarly, multi-dose injectable vials, if stored correctly in a refrigerator, must be discarded after a set time, such as 96 hours.


Q: Do studies support the use of Muclear for general respiratory health?

Official FDA labeling indicates the product is for use as an adjuvant therapy in patients with abnormal, thick, or viscid mucous secretions in specific bronchopulmonary conditions, such as chronic bronchitis or cystic fibrosis. Official labeling indicates a targeted, defined medical use and does not include a recommendation for general respiratory health.


Q: Is the research evidence for Muclear considered strong or limited?

The evidence base for Muclear's primary uses is considered sufficient for its official approval by global regulatory bodies. Its inclusion on the WHO Model List of Essential Medicines signifies established safety and efficacy for life-saving detoxification and its established use as a mucolytic agent.


Q: Are there official warnings about driving or operating machinery while on Muclear?

Regulatory documents indicate that no specific studies have been performed to assess the drug's effect on the ability to drive or use heavy machinery. However, the safety profile lists uncommon side effects, such as dizziness and headache, which may affect these abilities.


Q: Can people with kidney problems use Muclear?

Official product labeling specifies that when Muclear is used in the hospital as an antidote, a patient's renal function (kidney status) is a factor that is monitored throughout the course of treatment. Regulatory documents state that kidney status is a factor that healthcare providers consider closely when the drug is administered as an antidote.


Q: Is Muclear known to cause dizziness or drowsiness?

Official adverse reaction lists categorize side effects such as dizziness and headache as uncommon (meaning they affect less than 1 in 100 people) for some formulations of the drug. Drowsiness is not listed among the most common adverse reactions in regulatory documents.


Q: Can Muclear be taken with hot or cold beverages?

Specific temperature restrictions are usually not given in the regulatory labeling. Instructions require dissolving the powder or effervescent tablet in a small amount of water for drinking. The solution should be prepared in a way that does not risk degrading the active substance.


Q: Is there a maximum time Muclear should be used?

For its use as an antidote, the treatment is a short, fixed course (e.g., typically 20 or 21 hours). For its use as a mucolytic, regulatory documents indicate it may be continued for long-term maintenance in chronic conditions, implying that there is no fixed maximum duration for this specific indication.

Advertisements

How should Muclear (Acetylcysteine) be stored and disposed of?

Storage and Disposal of Acetylcysteine

Official regulations define specific conditions for storing Acetylcysteine to ensure product stability. Unopened injectable solution vials must be stored at Controlled Room Temperature (20°C to 25°C). The powder for oral solution must be stored at temperatures not exceeding 30°C.

Once opened or prepared, the product's shelf-life changes significantly. If only a portion of the oral/inhalation solution is used, the remainder must be stored in a refrigerator and used within 96 hours. Similarly, diluted injectable solutions and prepared effervescent tablet solutions must be used within 24 hours.

All forms of this medicine must be kept out of the sight and reach of children.

For disposal, unused or expired Acetylcysteine products should be handled in accordance with local regulations, often requiring disposal through a drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Muclear (Acetylcysteine) found in:

A-Z Index: